
This phase I zzso trial evaluated safety, efficacy and zzso of zzso a potent and selective second-generation inhibitor of vascular zzso growth factor zzso combined with platinum zzso in patients with advanced zzso cell lung cancer zzso and other solid zzso 

In all, 49 patients received zzso 5 zzso twice daily zzso with zzso or zzso in zzso zzso Following determination of the maximum tolerated dose, a zzso cell zzso expansion cohort was zzso and received zzso 5 zzso zzso with zzso 

Two patients experienced zzso zzso zzso zzso zzso in the zzso cohort and fatigue zzso in the zzso zzso Common zzso zzso adverse events were hypertension zzso zzso zzso and fatigue zzso No grade zzso zzso occurred among 12 patients with zzso cell zzso The objective response rate was zzso for patients receiving zzso zzso and zzso for patients receiving zzso zzso zzso of zzso and zzso agents were similar when administered alone or in zzso 

zzso 5 zzso zzso may be combined with standard zzso or zzso regimens without evidence of overt zzso zzso Both combinations demonstrated clinical efficacy and were well zzso 

